Compugen Ltd. (NASDAQ:CGEN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Compugen Ltd. (NASDAQ:CGEN) have earned an average rating of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $5.00.

A number of equities research analysts recently weighed in on CGEN shares. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen downgraded shares of Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Leerink Partners reduced their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, May 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Finally, Lake Street Capital began coverage on Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price target for the company.

Institutional Investors Weigh In On Compugen

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank Hapoalim BM purchased a new stake in shares of Compugen in the 4th quarter worth $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen during the fourth quarter valued at $38,000. Calamos Advisors LLC purchased a new position in shares of Compugen during the first quarter valued at $63,000. Franklin Resources Inc. bought a new stake in shares of Compugen in the second quarter valued at about $56,000. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Compugen in the first quarter valued at about $68,000. 12.22% of the stock is owned by institutional investors.

Compugen Stock Up 2.5%

CGEN stock opened at $2.47 on Friday. The business’s fifty day simple moving average is $2.41 and its two-hundred day simple moving average is $2.18. Compugen has a twelve month low of $1.29 and a twelve month high of $3.23. The firm has a market cap of $233.54 million, a price-to-earnings ratio of 6.68 and a beta of 2.76.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. Research analysts expect that Compugen will post -0.28 EPS for the current year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.